文献速递泌尿男性生殖肿瘤支持与姑息治疗

恩扎卢胺与阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌男性的疲乏、健康相关生活质量及代谢变化:HEAT随机临床试验

Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
PubMed 文献 · Eur J Cancer · 2022-06-13

这项单中心、开放标签、IV期随机试验纳入170例转移性去势抵抗性前列腺癌(mCRPC)患者,1:1随机接受恩扎卢胺(每日160 mg)或阿比特龙醋酸酯联合泼尼松(AAP,阿比特龙1000 mg+泼尼松10 mg每日)一线治疗。主要终点疲乏变化在AAP组更优(差异3.4分,95%CI 1.2;5.6,P=0.003);AAP组HbA1c升高更多(3.4 mmol/mol,95%CI 2.1;4.8,P=0.001),AAP组8例发生2型糖尿病,恩扎卢胺组0例。

要点

  • AAP组疲乏变化较恩扎卢胺组有临床意义改善(差异3.4分,95%CI 1.2;5.6,P=0.003)。
  • AAP组HbA1c升高较恩扎卢胺组更多(3.4 mmol/mol,95%CI 2.1;4.8,P=0.001)。
  • AAP组8例发生2型糖尿病,恩扎卢胺组0例;未观察到治疗相关严重不良事件。

核心结论

  • 在随机设置中,AAP较恩扎卢胺导致更少疲乏,但代价是HbA1c升高更多及2型糖尿病发生率更高。

研究设计与样本

  • 单中心、开放标签、IV期随机试验,纳入170例雄激素剥夺治疗进展的转移性前列腺癌患者,1:1随机接受恩扎卢胺(每日160 mg)或AAP(阿比特龙1000 mg+泼尼松10 mg每日)一线mCRPC治疗。
  • 所有结局在基线及12周随访时评估;试验注册号clinicaltrialsregister.eu 2017-000099-27。

主要发现

  • 主要终点疲乏变化在AAP组优于恩扎卢胺组,差异3.4分(95%CI 1.2;5.6,P=0.003),达临床意义。
  • 健康相关生活质量变化组间差异未达临床显著性。
  • AAP组HbA1c升高较恩扎卢胺组更多,差异3.4 mmol/mol(95%CI 2.1;4.8,P=0.001)。
  • AAP组8例发生2型糖尿病,恩扎卢胺组0例;未观察到治疗相关严重不良事件。

关键数值与推荐

  • 主要终点疲乏变化差异3.4分(95%CI 1.2;5.6,P=0.003),利于AAP。
  • HbA1c变化组间差异3.4 mmol/mol(95%CI 2.1;4.8,P=0.001),AAP组升高更多。
  • AAP组2型糖尿病8例,恩扎卢胺组0例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Enzalutamide and abiraterone acetate plus prednisone (AAP) have similar efficacy in metastatic castration-resistant prostate cancer (mCRPC). Herein, we compare fatigue, health-related quality-of-life (HRQoL) and metabolic changes in men with mCRPC treated with enzalutamide and AAP. MATERIALS AND METHODS: In this single-centre, open-labelled, phase IV trial, patients with metastatic prostate cancer progressing on androgen deprivation therapy were randomly assigned to enzalutamide (160 mg daily) or AAP (1000 mg abiraterone acetate and 10 mg prednisone daily) as first-line mCRPC treatment. The primary outcome was the difference in changed fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire). The secondary outcomes were differences in changed HRQoL (Functional Assessment of Cancer Therapy-Prostate questionnaire), body composition, weight, glucose homeostasis, lipid profile and blood pressure. All outcomes were assessed at baseline and at 12-week follow-up. TRIAL REGISTRATION: clinicaltrialsregister.eu (2017-000099-27). RESULTS: 170 patients were randomised (1:1) to enzalutamide or AAP. The primary outcome was positive with a clinically meaningful difference in fatigue, favouring AAP (3.4 points, 95% CI 1.2; 5.6, P = 0.003). The group difference in changed HRQoL did not reach clinical significance. The most important metabolic finding was a higher increase in glycated haemoglobin (HbA1c) for AAP than enzalutamide (3.4 mmol/mol, 95% CI 2.1; 4.8, P = 0.001). Eight patients developed type 2 diabetes (T2D) in the AAP group and none in the enzalutamide group. No treatment-related serious adverse event was observed. CONCLUSIONS: AAP resulted in less fatigue than enzalutamide in a randomised setting. This was at the expense of a higher HbA1c increase and incidence of T2D.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ternov KK, Sønksen J, Fode M, et al. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT). Eur J Cancer. 2022. PMID: 35709600. doi:10.1016/j.ejca.2022.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。